Bausch Health Companies

Synergetics USA, a medical device company, provides precision surgical devices, surgical equipment, and consumables primarily for the ophthalmology and neurosurgery markets in the United States and internationally. Its product lines focuses upon precision engineered disposable and reusable devices, surgical equipment, procedural kits, and the delivery of various energy modalities that include laser energy, ultrasonic energy, radio frequency energy for electro surgery and lesion generation, and visible light energy for illumination. Synergetics USA offers approximately 1,000 separate catalogue items in the vitreoretinal surgical market that include vitrectomy system under the VersaVIT 2.0 brand; procedural packs under VersaPACK and Core Essentials brands; fiberoptic endoilluminators and endolaser probes; various disposable and reusable devices designed for intraocular manipulation of tissues; illumination equipment under the Photon brand; laser equipment for the United States market under Ellex’s Solitaire brand; Volk’s line of ophthalmic lenses; Labtician’s scleral buckles; and other miscellaneous products. It sells its products directly as well as through distributors and independent sales representatives to end-users at hospitals, ambulatory surgery centers, and surgeon offices. Synergetics USA began operation in 1991, with its headquarters in O'Fallon in Missouri. It operates as a subsidiary of Valeant Pharmaceuticals International as of October 14, 2015.

Sprout Pharmaceuticals develops products for the treatment of female sexual dysfunction. They're committed to breakthrough firsts in women’s sexual health. The company was incorporated in 2011 and is based in Raleigh, North Carolina.

Amoun’s main business includes development, manufacturing, marketing, distribution, and export of a wide range of human pharmaceutical and animal health products. Amoun maintains a robust product portfolio that offers a wide range of much needed pharmaceutical therapies and treatments. With a strong product pipeline strategy, Amoun currently has more than 30 new product at various stages of registration that were carefully selected in order to address many un-met therapeutic needs, such as high prevalence diseases and other diseases of high national interest. Amoun’s product portfolio and product pipeline will endure further expansions for many years to come and will continue to play a major role in driving growth and in increasing shareholders’ value.

Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders. For more than 20 years, they have licensed, developed, and marketed innovative products to treat GI problems. It's their mission to give healthcare providers and patients the most effective solutions in gastroenterology.

Seattle-based biotechnology company focused on targeting cancer to transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is also developing an orally-available small molecule targeting TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia.

Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Solta Medical, Inc. designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications. Its products include Thermage NXT system that provides non-invasive treatment options for skin tightening and contouring, body shaping, and enhancement in the appearance of cellulite; Fraxel re:fine and Fraxel re:store systems, which offer treatments for skin conditions, such as fine lines and pigmentation; and Fraxel re:pair system for dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, as well as for rhytids, pigmentation, and vascular dyschromia. The company's Fraxel re:store system also offers treatments for acne and surgical scars, deeper lines and wrinkles, and actinic keratoses. Its systems consist of one or more handpieces, a console that incorporates a graphical user interface, an energy source and electronics, and a disposable treatment tip. The company's customers include dermatologists, plastic surgeons, general and family practitioners, gynecologists, and ophthalmologists. Solta Medical markets its systems and treatment tips through direct sales force and a network of distributors in the United States and internationally. The company was formerly known as Thermage, Inc. and changed its name to Solta Medical, Inc. in January 2009. Solta Medical was founded in 1995 and is headquartered in Hayward, California.

Bausch + Lomb is a global eye health business of Bausch Health Companies, Inc., is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.

Obagi Medical Products is a specialty pharmaceutical company that develops and markets skin care products. Obagi Medical Products offers a range of products that are categorized under transformation systems, essential products, targeted solutions, skin recovery, and in-office procedures. It facilitates a website that enables its users to find information about its products and tips related to skin care. Obagi Medical Products was founded in 1988 and is based in Long Beach, California.

Medicis Pharmaceutical is a pharmaceutical and medical product development and manufacturing company. They create, manufacture, and sell a variety of goods, primarily in gastroenterology, neurology, dermatology, and worldwide pharmaceuticals.

Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye. The company conducted research and development into wet age-related macular degeneration diseases, which was seen as a breakthrough in the field. Valeant Pharmaceuticals International acquired Eyetech for US$22 million in 2012.

Probiótica Laboratórios offers food supplements with a focus on sports nutrition.

iNova Pharmaceuticals develops and markets a range of over-the-counter and prescription medicines to Australia and New Zealand. Our focus is to improve human health and well-being by providing valued pharmaceutical products and services to patients and consumers. Our product portfolio includes weight management, pain management, dermatology, cardiology, respiratory health and allergy.

Dermik Laboratories offers therapeutic products to treat acne, actinic keratosis, dermatitis and eczema, insect bites and stings, plant rashes, psoriasis, rosacea, and rough skin; aesthetic products, including HIV facial lipoatrophy products, chemical peels for revitalizing, and skin hydration products; and podiatric products for nail fungus.

PharmaSwiss SA develops and manufactures generics and over-the-counter pharmaceutical products.

Aton Pharma, Inc. operates as a specialty pharmaceutical company. It focuses on ophthalmic diseases, orphan conditions, and acute care hospital products. The company offers products for metabolic, neurological, and cardiovascular diseases, as well as provides products for under-treated diseases, including dry eye. Its products include timolol maleate ophthalmic gel forming solution for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The company serves patients, caregivers, and healthcare professionals in the United States, the Asia Pacific region, Australia, and internationally. Aton Pharma, Inc. was formerly known as Avatar. The company was founded in 2001 and is based in Lawrenceville, New Jersey. Aton Pharma, Inc. is a former subsidiary of Merck & Co., Inc.

Private Formula International is a privately owned medium sized Australian company. It owns and distributes the Dr LeWinns brand through department stores and pharmacies nationally as well as internationally. With 50+ staff based in Australia, the company is a leading innovator of anti-ageing skincare products and treatments providing its consumers with quality products that work at an accessible price point. Private Formula International head office is located at 460 Bay Street, Port Melbourne, Victoria. The company outsources its manufacturing activities through 3 overseas and 4 local suppliers. Private Formula has always been mindful of the potential impact on waste disposals in general and has been concerned on how the global environment changes could impact the future. Private Formula has recently being made aware of a structured organization in this area ie. National Packaging Covenant and fully supports its principles and goals hence, the company is now a signatory of the organization.

Tecnofarma is a Mexican pharmaceutical company dedicated to producing a wide range of interchangeable generic (GI), for the IMSS, ISSSTE, Marine and Department Stores, as well as its own line of drugs.

Dow Pharmaceutical Sciences, Inc. engages in the development of topical drug products for pharmaceutical and biotechnology clients.

DermTech, Inc. is a molecular diagnostic company based in La Jolla, California, focused on developing and marketing non-invasive diagnostic tests for skin cancer and related conditions in the United States. The company offers the Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and eliminates the need for surgical biopsies of atypical pigmented lesions. Additionally, DermTech provides the Nevome test, an adjunctive reflex test for the PLA, along with adhesive skin sample collection kits and gene expression assays targeting specific inflammatory pathways. The firm is also working on diagnostic products for non-melanoma skin cancer and risk assessment. DermTech generates revenue primarily by selling its products to pathology and oncology practitioners, and its assays are performed at a CLIA-certified laboratory in San Diego, utilizing adhesive tape biopsy methods to collect skin samples non-invasively.

DermaTech Pty Ltd is an Australian company specializing in the development, production and distribution of innovative products to address common dermatological conditions such as dry, itchy or sensitive skin, acne, eczema, psoriasis, contact dermatitis, insect bites, skin warts and sunburn.

Coria Laboratories, Ltd. is a privately held pharmaceutical company based in Fort Worth, Texas, specializing in research, development and marketing of branded prescription and over-the-counter dermatology products. The company also provides products for dermatomes, atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, hyperkeratotic skin disorders, ichthyosis, psoriasis, and keratosis pilaris.

Xcel Pharmaceuticals are a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system (CNS). They currently focus on neurology, a segment of the CNS market where a limited number of high-prescribing physicians write a significant number of the prescriptions for neurology products. Their product portfolio consists of four commercial products and two product candidates. Their commercial products include two epilepsy products, Diastat® and Mysoline®, and two migraine products, Migranal® and D.H.E. 45®. Their product candidates include MT 300™, a potential treatment for migraine, and retigabine, a potential treatment for epilepsy. their nationwide field sales organization promotes their products to high-prescribing epilepsy and migraine specialists. Their strategy is to increase prescription demand for Their lead products through targeted sales and marketing efforts, to successfully develop and commercialize Their late-stage development product candidates, to leverage Their CNS presence through the acquisition of additional late-stage development product candidates and commercial products, and to develop enhancements for Their current products. Their corporate infrastructure is designed to support Their field sales organization, to manage Their product development efforts, to identify and pursue the acquisition of additional late-stage development product candidates and commercial products, and to manage Their product enhancement efforts. They have developed valuable relationships with experts and third-party consultants that They intend to utilize for the advancement of late-stage development product candidates, including retigabine, through the development and regulatory approval process. They also utilize third parties to manufacture and distribute Their products and to support Their product development and enhancement efforts.

A leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight.